VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U ...

Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year Cancer is ...

The WVC Annual Conference is one of the largest and longest-running veterinary conferences in the country. WVC offers hundreds of educational opportunities, including lectures, hands-on CE labs, and ...

AUSTIN, Nov. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the world's leading veterinary education conference, ...

HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co ...

HENDERSON, Nev., Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate ...

AUSTIN, Texas, April 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted by Texas A&M University ...

HENDERSON, Nev., Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test ...

HENDERSON, Nev., Feb. 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is pleased to announce our participation in the ...